biotech · Bladder Cancer · Non Muscle Invasive Bladder Cancer · CGON
CG Oncology
CG Oncology patent portfolio — 5 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Dallas, USA
- Founded
- 2010
- Employees
- 187
- Programs
- 8
- Drugs
- 1
- Patents
- 5
CG Oncology patents
5 pharmaceutical patents indexed for CG Oncology. 0 expire within 24 months.
CG Oncology has 5 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12370229
Methods of treating bladder cancer
granted -
US 12090183
Methods of treating solid or lymphatic tumors by combination therapy
granted -
US 11596660
Methods of treating bladder cancer
granted -
US 11497781
Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
granted -
US 11338003
Methods of treating bladder cancer with an oncolytic virus
granted
Frequently asked questions
How many patents does CG Oncology have?
5 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do CG Oncology patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.